The fact that there exist established CSF biomarkers for Alzheimer’s disease (Tau, p-tau, Aβ-42) spurs interest in finding a specific CSF biomarker for PD to support the clinical diagnosis of this disease. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.